Octreotide Acetate Pen Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 25000 mcg, 7000 mcg

Reference Brands: Bynfezia Pen (USA)

Category: Oncology Cancer Care

Octreotide (brand Sandostatin®) is used to treat carcinoid tumors, acromegaly, and GEP-NETs. Available in subcutaneous injections (0.5 mg/mL, 1 mg/mL, 3 mg/mL) and long-acting formulations (Sandostatin LAR®) (10 mg, 20 mg, 30 mg), it controls tumor-related symptoms like diarrhea and flushing by inhibiting hormone release. Available through GMP-compliant suppliers in the US and EU for oncology treatment. Octreotide acetate Pen is available in injection (prefilled syringe) and strengths such as 25000 mcg, 7000 mcg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Octreotide acetate Pen is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Octreotide acetate Pen can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Octreotide, marketed under the brand name Sandostatin®, is a somatostatin analogue used in oncology to manage carcinoid tumors, acromegaly, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Available as subcutaneous injections (0.5 mg/mL, 1 mg/mL, 3 mg/mL) and long-acting injections (Sandostatin LAR®) (10 mg, 20 mg, 30 mg), it works by inhibiting hormone secretion, controlling tumor-induced symptoms like diarrhea and flushing. Sourced from GMP-certified suppliers, Octreotide is widely available for global distribution in US and EU markets. It provides reliable therapeutic options for oncologists and healthcare providers treating complex neuroendocrine tumors.